123 related articles for article (PubMed ID: 25018102)
1. Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation.
Limone BL; Baker WL; Mearns ES; White CM; Kluger J; Coleman CI
J Clin Epidemiol; 2014 Oct; 67(10):1093-102. PubMed ID: 25018102
[TBL] [Abstract][Full Text] [Related]
2. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models.
Limone BL; Baker WL; Kluger J; Coleman CI
PLoS One; 2013; 8(4):e62183. PubMed ID: 23626785
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
4. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Kamel H; Johnston SC; Easton JD; Kim AS
Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
Janzic A; Kos M
Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
[TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.
Sullivan PW; Arant TW; Ellis SL; Ulrich H
Pharmacoeconomics; 2006; 24(10):1021-33. PubMed ID: 17002484
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
Nguyen E; Egri F; Mearns ES; White CM; Coleman CI
Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of oral anticoagulants for nonvalvular atrial fibrillation patients at the police general hospital, Bangkok, Thailand.
Jarungsuccess S; Taerakun S
Clin Ther; 2014 Oct; 36(10):1389-94.e4. PubMed ID: 25267360
[TBL] [Abstract][Full Text] [Related]
13. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
17. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
O'Brien CL; Gage BF
JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
Lanitis T; Kongnakorn T; Jacobson L; De Geer A
Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.
Li X; Tse VC; Lau WC; Cheung BM; Lip GY; Wong IC; Chan EW
PLoS One; 2016; 11(6):e0157129. PubMed ID: 27362421
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting.
Morais J; Aguiar C; McLeod E; Chatzitheofilou I; Fonseca Santos I; Pereira S
Rev Port Cardiol; 2014 Sep; 33(9):535-44. PubMed ID: 25241380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
